Abstract
In early December 2019, an outbreak of coronavirus 2019 (COVID-19) caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, China's Hubei province. On 30 January 2020, the World Health Organization and International Public Health declared the outbreak an emergency, and as of 23.03.2021, laboratory-approved 123,097,155 cases and 2,716,151 deaths were reported worldwide. The perceived risk of disease has led many countries to adopt various control measures. Emerging genetic and clinical evidence suggests a pathway similar to SARS and MERS. Potential therapeutic strategies that are currently being evaluated derive mainly from previous experience with Covid-19 treatment. Although several potential treatments for COVID-19 with SARS and MERS have been identified in animal and in vitro models, human clinical trials are still lacking, which hinders the progress of potential measures. This review requires an overview of the three major deadly coronaviruses and an assessment of risk factors applicable lessons to stop their spread by leveraging lessons learned from the first two deadly coronavirus outbreaks by identifying areas for improvement in future preparedness plans. The first lessons from the persistence and spread of the outbreak can help inform public health officials and medical practitioners in their efforts to combat its progress. Also, in this review, the pathogenesis, epidemiology, diagnosis, treatment, and vaccine strategies of the disease are reviewed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
